Abstract
Natural antibodies are preformed antibodies that are present even in naive germ-free mice in the absence of any exogenous antigenic exposure. Consistent with their specificities for microbial antigens, natural antibodies play an important non-redundant role in the first line defense against bacterial and viral infections. On the other hand natural antibodies have also been shown to have specificities for self antigens, and therefore have been proposed to provide important homeostatic “house-keeping” functions. Many of the recognized self-antigens may in fact be stress-induced self-antigens, such as oxidation-specific epitopes that accumulate during atherogenesis as well as in many other inflammatory settings, and natural antibodies could protect from the impact of the pathological accumulation of these self-antigens. In this review we will discuss the specific example of the prototypic natural antibody T15/EO6, which is increased in atherosclerotic mice and mediates atheroprotection, and discuss the potential role of natural antibodies in atherogenesis in general.
Current Drug Targets
Title: Natural Antibodies in Murine Atherosclerosis
Volume: 9 Issue: 3
Author(s): Joseph L. Witztum, Christoph J. Binder, Meng-Yun Chou, Linda Fogelstrand, Karsten Hartvigsen, Peter X. Shaw and Agnes Boullier
Affiliation:
Abstract: Natural antibodies are preformed antibodies that are present even in naive germ-free mice in the absence of any exogenous antigenic exposure. Consistent with their specificities for microbial antigens, natural antibodies play an important non-redundant role in the first line defense against bacterial and viral infections. On the other hand natural antibodies have also been shown to have specificities for self antigens, and therefore have been proposed to provide important homeostatic “house-keeping” functions. Many of the recognized self-antigens may in fact be stress-induced self-antigens, such as oxidation-specific epitopes that accumulate during atherogenesis as well as in many other inflammatory settings, and natural antibodies could protect from the impact of the pathological accumulation of these self-antigens. In this review we will discuss the specific example of the prototypic natural antibody T15/EO6, which is increased in atherosclerotic mice and mediates atheroprotection, and discuss the potential role of natural antibodies in atherogenesis in general.
Export Options
About this article
Cite this article as:
Witztum L. Joseph, Binder J. Christoph, Chou Meng-Yun, Fogelstrand Linda, Hartvigsen Karsten, Shaw X. Peter and Boullier Agnes, Natural Antibodies in Murine Atherosclerosis, Current Drug Targets 2008; 9 (3) . https://dx.doi.org/10.2174/138945008783755520
DOI https://dx.doi.org/10.2174/138945008783755520 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gold Salts Therapy in Respiratory Diseases
Current Respiratory Medicine Reviews An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Alternative Aβ Immunotherapy Approaches for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Cardiovascular Risk, Inflammation and Physical Activity in Rheumatoid Arthritis
Current Rheumatology Reviews Inflammasome Activation in Chronic Glomerular Diseases
Current Drug Targets Survey of Epstein Barr Virus (EBV) Immunogenic Proteins and their Epitopes: Implications for Vaccine Preparation
Recent Patents on Anti-Infective Drug Discovery Lysophosphatidic Acid and Renal Fibrosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Antitumor Activity of Benzamide Riboside In Vitro and In Vivo
Current Medicinal Chemistry Heterologous Production of Death Ligands’ and Death Receptors’ Extracellular Domains: Structural Features and Efficient Systems
Protein & Peptide Letters Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Recent Drug Targets Associated to Abnormal Signal Transduction Mediated Cancer, Rheumatoid Arthritis, Alzheimer’s and Parkinson’s disease
Current Signal Transduction Therapy Editorial [Hot topic: Immunological Regulation of the Central Nervous System: From Physiological to Pathological Processes (Guest Editor: Oscar Gonzalez-Perez)]
Current Immunology Reviews (Discontinued) Oxidative Stress in Autoimmune Diseases: An Under Dealt Malice
Current Protein & Peptide Science Development of Bruton’s Tyrosine Kinase Inhibitors for Rheumatoid Arthritis
Current Medicinal Chemistry Chemical Modifications of Ketoprofen (NSAID) in Search of Better Lead Compounds: A Review of Literature From 2004-2016
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis, Design and Anti-inflammatory Activity of Novel 5-(Indol-3- yl)thiazolidinone Derivatives as COX-2 Inhibitors
Letters in Drug Design & Discovery Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition NOS: Molecular Mechanisms, Clinical Aspects, Therapeutic and Monitoring Approaches
Current Drug Targets - Inflammation & Allergy Immunomodulatory Role of Arsenic in Regulatory T Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Meet Our Editorial Board Member
Current Drug Targets